NXTC Q4 2020 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$35M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$16M

Net Income

-$15M

EPS (Diluted)

$-6.73

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$307M

Total Liabilities

$13M

Stockholders' Equity

$294M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$2M	-100.0%
Gross Profit	$0	-$9M	+100.0%
Operating Income	-$16M	-$12M	-35.2%
Net Income	-$15M	-$11M	-41.5%